Program
xanomeline
Also written as “KarXT”, “Xanomeline and Trospium Chloride Capsules” and “KarX-EC”.
Its studies are mostly in Schizophrenia · Alzheimer Disease · Mania · Autism Spectrum Disorder · Nausea, led by Bristol-Myers Squibb.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 3825 open or running | phase 4since Oct 13, 2025 | Oct 3, 2018 | Nov 24, 2026phase 3 · NCT06585787 |
Also a collaborator on its studies: Zai Lab.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Oct 3, 2018.
- Mar 17, 2025Phase 3 study in SchizophreniaNCT06882785 · 250 planned · Japan
- Apr 14, 20255 phase 3 studiesNCT06929273, NCT06937229, NCT06951711 and 2 more
- May 9, 20252 phase 3 studies in Alzheimer DiseaseNCT06976216, NCT06976203
- Jun 2, 20252 phase 3 studies in Alzheimer DiseaseNCT07011745, NCT07011732
- Jun 23, 2025Phase 1 study in Healthy VolunteersNCT07063342 · 236 planned · United Kingdom
- Jul 2, 2025Phase 1 study in SchizophreniaNCT07061288 · 131 planned · United States
- Aug 21, 2025Phase 3 study in ManiaNCT07140913 · 424 planned · United States, Argentina, Bulgaria and more
- Sep 24, 2025Phase 1 study in Healthy VolunteersNCT07204418 · 56 planned · United States
- Oct 13, 2025Phase 4 study in SchizophreniaNCT07221877 · 60 planned · United States
- Nov 21, 2025Phase 4 study in Healthy VolunteersNCT07257120 · 10 enrolled · United States
- Dec 9, 20253 phase 3 studiesNCT07284745, NCT07285798, NCT07288567
- Feb 13, 2026Phase 3 study in SchizophreniaNCT07424404 · 400 planned · United States, Australia, Canada and more
- Jun 26, 2026Phase 4 study in NauseaNCT07681076 · 180 planned · United States
- Jun 30, 2026Phase 3 study in SchizophreniaNCT07686263 · 472 planned · United States, Argentina, Bulgaria and more
Ahead
- Nov 1, 2026Primary completion: phase 3 study in ManiaNCT06951698
- Nov 2, 2026Primary completion: phase 3 study in ManiaNCT06951711
- Nov 24, 2026Primary completion: phase 3 study in Alzheimer DiseaseNCT06585787
- Nov 30, 2026Primary completion: phase 4 study in NauseaNCT07681076
TargetBeta
“Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist; Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07686263Schizophrenia · United States, Argentina, Bulgaria and more | 3 | Recruiting | Mar 3, 2029 | 472 |
| NCT07681076Nausea · United States | 4 | Recruiting | Nov 30, 2026 | 180 |
| NCT07424404Schizophrenia · United States, Australia, Canada and more | 3 | Recruiting | Mar 8, 2030 | 400 |
| NCT07288567Schizophrenia · United States, Colombia, Japan and more | 3 | Recruiting | Dec 18, 2029 | 166 |
| NCT07285798Autism Spectrum Disorder · United States, France, Germany and more | 3 | Recruiting | Aug 6, 2029 | 176 |
| NCT07284745Autism Spectrum Disorder · United States, Australia, Canada and more | 3 | Recruiting | Aug 6, 2029 | 176 |
| NCT07257120Healthy Volunteers · United States | 4 | Completed | Jun 8, 2026 | 10 |
| NCT07221877Schizophrenia · United States | 4 | Recruiting | Dec 30, 2027 | 60 |
| NCT07204418Healthy Volunteers · United States | 1 | Recruiting | Dec 3, 2026 | 56 |
| NCT07140913Mania · United States, Argentina, Bulgaria and more | 3 | Recruiting | Jun 28, 2027 | 424 |
| NCT07061288Schizophrenia · United States | 1 | Recruiting | Jun 21, 2027 | 131 |
| NCT07063342Healthy Volunteers · United Kingdom | 1 | Recruiting | Mar 29, 2027 | 236 |
| NCT07011745Alzheimer Disease · United States, Argentina, Chile and more | 3 | Recruiting | Nov 3, 2028 | 426 |
| NCT07011732Alzheimer Disease · United States, Argentina, Brazil and more | 3 | Recruiting | Nov 24, 2028 | 426 |
| NCT06976216Alzheimer Disease · United States, Argentina, Australia and more | 3 | Recruiting | Sep 11, 2028 | 586 |
| NCT06976203Alzheimer Disease · United States, Argentina, Australia and more | 3 | Recruiting | Sep 11, 2028 | 586 |
| NCT06947941Alzheimer Disease · United States, Australia, Canada and more | 3 | Recruiting | Feb 21, 2028 | 325 |
| NCT06951711Mania · United States, China, Croatia and more | 3 | Recruiting | Nov 2, 2026 | 274 |
| NCT06951698Mania · United States, Argentina, Australia and more | 3 | Recruiting | Nov 1, 2026 | 274 |
| NCT06937229Alzheimer Disease · United States, Argentina, Brazil and more | 3 | Recruiting | Jun 22, 2029 | 650 |
| NCT06929273Mania · United States, Argentina, Australia and more | 3 | Recruiting | Jun 13, 2028 | 450 |
| NCT06882785Schizophrenia · Japan | 3 | Recruiting | Sep 23, 2028 | 250 |
| NCT06853171Mental Disorders · United States | 1 | Completed | Jul 22, 2025 | 24 |
| NCT06605950Healthy Volunteers · United States | 1 | Completed | May 31, 2025 | 78 |
| NCT06585787Alzheimer Disease · United States, Argentina, Belgium and more | 3 | Recruiting | Nov 24, 2026 | 406 |
| NCT06572449Schizophrenia · United States | 3 | Completed | Mar 13, 2025 | 173 |
| NCT06126224Psychosis Associated With Alzheimer's Disease · United States, Belgium, Canada and more | 3 | Recruiting | Dec 9, 2026 | 500 |
| NCT05980949Psychosis Associated With Alzheimer's Disease · United States, Argentina, Belgium and more | 3 | Recruiting | Sep 7, 2027 | 1,000 |
| NCT05919823Schizophrenia · China | 3 | Completed | Sep 16, 2024 | 202 |
| NCT05643170Schizophrenia · United States | 3 | Terminated | Mar 1, 2023 | 4 |
| NCT05511363Psychosis Associated With Alzheimer's Disease · United States, Bulgaria, Croatia and more | 3 | Recruiting | Oct 5, 2026 | 410 |
| NCT05304767Schizophrenia · United States, Bulgaria, Japan and more | 3 | Completed | Mar 25, 2026 | 290 |
| NCT05145413Schizophrenia · United States, Bulgaria, India and more | 3 | Completed | Mar 19, 2025 | 396 |
| NCT04820309Schizophrenia · United States, Puerto Rico | 3 | Completed | May 24, 2024 | 566 |
| NCT04738123Schizophrenia · United States, Ukraine | 3 | Completed | Nov 29, 2022 | 256 |
| NCT04659174Schizophrenia · United States, Ukraine | 3 | Completed | Oct 3, 2023 | 152 |
| NCT04659161Schizophrenia · United States | 3 | Completed | May 24, 2022 | 252 |
| NCT03697252Schizophrenia · United States | 2 | Completed | Sep 4, 2019 | 182 |
How it is read
Names in the registry
- “KarXT”, 21 entries
- “Xanomeline and Trospium Chloride Capsules”, 9 entries
- “KarX-EC”, 7 entries
- “Xanomeline Enteric Capsule”, 3 entries
- “Xanomeline/trospium chloride”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 16 studies
- Alzheimer Disease, 10 studies
- Mania, 4 studies
- Autism Spectrum Disorder, 2 studies
- Nausea, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.